Insider Selling: Natera (NASDAQ:NTRA) Director Sells 11,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Natera Price Performance

Natera stock traded up $9.35 during mid-day trading on Tuesday, reaching $222.82. 1,209,573 shares of the company traded hands, compared to its average volume of 1,440,794. The firm’s 50 day moving average price is $205.34 and its 200 day moving average price is $216.16. The firm has a market capitalization of $31.91 billion, a price-to-earnings ratio of -136.70 and a beta of 1.56. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on NTRA shares. Wolfe Research initiated coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Evercore restated an “outperform” rating and set a $270.00 target price on shares of Natera in a report on Friday, May 8th. Wells Fargo & Company boosted their target price on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday. They set a “neutral” rating and a $245.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $256.12.

Institutional Trading of Natera

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC boosted its stake in Natera by 3.4% in the 1st quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock worth $1,090,000 after purchasing an additional 179 shares in the last quarter. Groupama Asset Managment boosted its stake in Natera by 3.0% in the 1st quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock worth $19,011,000 after purchasing an additional 2,805 shares in the last quarter. Oddo BHF Asset Management Sas bought a new position in Natera in the 1st quarter worth about $6,410,000. Bull Harbor Capital LLC bought a new position in Natera in the 1st quarter worth about $1,543,000. Finally, Encore Global Management LP bought a new position in Natera in the 1st quarter worth about $1,200,000. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.